NCT02728492 - Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

Non-small Cell Lung CancerEpithelial Ovarian Cancer

Interventions

DRUG

Quisinostat

DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Gemcitabine

DRUG

Cisplatin

Trial Locations (6)

115478

Russian Oncological Research Center n.a. N. N. Blokhin RAMS, Moscow

150054

"State Healthcare Institution of Yaroslavl region Regional Clinical oncology hospital", Yaroslavl

197022

"Saint-Peterburg State Budgetary healthcare Institution City Clinical Oncology Dispensary", Saint Petersburg

197342

BioEq LLC, Saint Petersburg

197758

"State Budget Institution of healthcare Saint-Petersburg clinical research and practical centre of specialized medical aid (oncology)", Saint Petersburg

357502

"State Budgetary Healthcare Institution of Stavropol Territory Pyatigorsk oncology dispensary", Pyatigorsk